About_editors 1..1 - Free

74 Firsov et al.In Program and Abstracts of the IXth International Congress of Infectious and ParasiticDiseases, 1986, abstr. No.1394.60. White CA, Toothaker RD. Influence of ampicillin elimination half-life on in-vitro bactericidaleffect. J Antimicrob Chemother 1985; 15(suppl A):257–260.61. Wiedemann B, Jansen A. Antibacterial activity of cefpodoxime proxetil in a pharmacokineticin-vitro model. J Antimicrob Chemother 1990; 26:71–79.62. Firsov AA, Savarino D, Ruble M, Gilbert D, Manzano B, Medeiros AA, Zinner SH.Predictors of effect of ampicillin-sulbactam against TEM-1 beta- lactamase-producingEscherichia coli in an in vitro dynamic model: enzyme activity versus MIC. AntimicrobAgents Chemother 1996; 40:734–738.63. Shah PM. Bactericidal activity of ceftazidime against Pseudomonas aeruginosa under conditionssimulating serum pharmacokinetics. J Antimicrob Chemother 1981; 8:135–140.64. Firsov AA, Zinner SH, Vostrov SN, Portnoy YA, Lubenko IY. AUC/MIC relationships todifferent endpoints of the antimicrobial effect: multiple-dose in vitro simulations withmoxifloxacin and levofloxacin. J Antimicrob Chemother 2002; 50:533–539.65. Firsov AA, Lubenko IY, Portnoy YA, Zinner SH, Vostrov SN. Relationships of the areaunder the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacinpharmacodynamics in an in vitro dynamic model. Antimicrob Agents Chemother2001; 45:927–931.66. Zinner SH, Lubenko IY, Gilbert D, et al. Emergence of resistant Streptococcus pneumoniae inan in vitro dynamic model that simulates moxifloxacin concentrations inside and outsidethe mutant selection window: related changes in susceptibility, resistance frequency andbacterial killing. J Antimicrob Chemother 2003; 52:616–622.67. Firsov AA, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH. Anti-staphylococcal effectrelated to the area under the curve/MIC ratio in an in vitro dynamic model: predictedbreakpoints versus clinically achievable values for seven fluoroquinolones. AntimicrobAgents Chemother 2005; 49:2642–2647.68. Firsov A, Lubenko I, Vostrov S, Alferova I, Smirnova M, Zinner S. Comparative pharmacodynamicsof daptomycin and vancomycin with Staphylococcus aureus in an in vitro dynamicmodel: focus on the clinically achievable ratios of area under the curve (AUC) to MIC. Int JAntimicrob Agents 2004; 24:111.69. Zinner S, Smirnova M, Alferova I, et al. Comparative pharmacodynamics of daptomycinand vancomycin with Staphylococcus aureus: multiple-dose simulations using an in vitrodynamic model. Clin Microbiol Infection 2005; 11:518.70. Wright DH, Hovde LB, Peterson ML, Hoang AD, Rotschafer JC. In vitro dose-rangingevaluation of fluoroquinolone pharmacodynamic parameters against Streptococcus pneumoniae.J Antimicrob Chemother 2001; 47:42.71. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic(PK/PD) terminology for anti-infective drugs: an update. J AntimicrobChemother 2005; 55:601–607.72. Macgowan AP, Bowker KE, Wootton M, Holt HA. Activity of moxifloxacin, administeredonce a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model ofinfection. Antimicrob Agents Chemother 1999; 43:1560–1564.73. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC. Twenty-four-hour area underthe concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobialeffect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamicmodel. Antimicrob Agents Chemother 1996; 40:627–632.74. Firsov AA, Vasilov RG, Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH. Predictionof the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using anin-vitro dynamic model. J Antimicrob Chemother 1999; 43:483–490.75. Firsov AA, Zinner SH, Lubenko IY, Vostrov SN. Gemifloxacin and ciprofloxacin pharmacodynamicsin an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpointsand doses. Int J Antimicrob Agents 2000; 16:407–414.76. Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH, Firsov AA. Comparative pharmacodynamicsof gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction ofequiefficient doses and the breakpoints of the area under the curve/MIC ratio. AntimicrobAgents Chemother 2000; 44:879–884.